Intercept Pharma (ICPT) Announces Repurchase of Convertible Notes

Go back to Intercept Pharma (ICPT) Announces Repurchase of Convertible Notes

Intercept Pharmaceuticals Announces Repurchase of Convertible Notes

August 19, 2022 7:30 AM UTC

MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into privately negotiated agreements to repurchase $327.9 million of its secured convertible debt using a combination of cash and equity. The repurchase is expected to close promptly, subject to and following customary closing conditions.

This action is the most recent in a series of strategic financial moves undertaken by the Company over the past 12 months to improve its... More